OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zauderer on Emerging Treatment Strategies in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

November 5th 2021

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer.

Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC

November 5th 2021

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Dr. Davidson on Leveraging Imaging Technologies to Inform Clinical Decisions in Breast Cancer

November 4th 2021

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Dr. Hanna on the Role of Second-Line Cetuximab in Head and Neck Cancer

November 4th 2021

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

Dr. Mato Discusses Advances in the Treatment of Patients With CLL

November 4th 2021

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Dr. Chari on the Role of MRD Testing in Multiple Myeloma

November 4th 2021

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

Dr. Foss on Pursuing New Therapeutic Options in T-Cell Non-Hodgkin Lymphoma

November 3rd 2021

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

Dr. Albitar on the Importance of Obtaining Genomic Testing in Oncology

November 3rd 2021

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

Dr. Kremyanskaya on the Need for Disease-Modifying Approaches in MPNs

November 3rd 2021

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Dr. Kuykendall on the Potential for Momelotinib in Myelofibrosis

November 2nd 2021

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

November 2nd 2021

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Dr. Baron on Contributing Factors for Developing Breast Cancer

November 2nd 2021

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

November 2nd 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Dr. Palmbos on Frontline Treatment Recommendations in Bladder Cancer

November 2nd 2021

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.

Dr. Hubbard on MRD Assessment to Inform Treatment Decisions in Resected Metastatic CRC

November 2nd 2021

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Dr. Danilov on the Rationale to Target MCL1 and BCLX in CLL

November 1st 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Dr. Sabari on Selecting Between Available ALK inhibitors in ALK+ NSCLC

November 1st 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Dr. Yentz on Navigating Frontline Treatment Selection in RCC

November 1st 2021

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Dr. Salani on Future Research Opportunities in Recurrent Ovarian Cancer

October 29th 2021

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.